Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Down 9.7% in March

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 283,100 shares, a decline of 9.7% from the March 15th total of 313,400 shares. Based on an average trading volume of 2,290,000 shares, the days-to-cover ratio is presently 0.1 days.

Avenue Therapeutics Trading Up 5.3 %

Shares of ATXI stock opened at $0.13 on Wednesday. Avenue Therapeutics has a 1 year low of $0.11 and a 1 year high of $1.28. The firm’s fifty day simple moving average is $0.15 and its 200 day simple moving average is $0.22. The firm has a market capitalization of $5.82 million, a P/E ratio of -0.10 and a beta of -0.24.

Avenue Therapeutics (NASDAQ:ATXI) last announced its quarterly earnings results on Monday, March 18th. The company reported $0.56 earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Avenue Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in Avenue Therapeutics in the 1st quarter valued at $28,000. Renaissance Technologies LLC bought a new stake in Avenue Therapeutics in the 2nd quarter valued at $34,000. State Street Corp bought a new stake in Avenue Therapeutics in the 1st quarter valued at $36,000. Geode Capital Management LLC boosted its stake in shares of Avenue Therapeutics by 359.9% in the 2nd quarter. Geode Capital Management LLC now owns 52,571 shares of the company’s stock valued at $60,000 after purchasing an additional 41,141 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of Avenue Therapeutics in the 3rd quarter valued at $145,000. Institutional investors own 17.34% of the company’s stock.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.